Business Wire

Hempyre Holdings Ltd. Launches Global Platform for Branded Hemp-Formulated Consumer Packaged Goods

28.4.2020 13:00:00 EEST | Business Wire | Press release

Share

Hempyre Holdings Ltd. (“Hempyre” or the “Company”) is pleased to announce the launch of a global distribution platform of branded hemp-formulated consumer packaged goods focused on beauty, beverage, and wellness.

Headquartered in London, Hempyre has agreed to acquire CMLM Holdings, Inc., dba QIND, a U.S.-based provider of hemp-formulated wellness and beauty products featuring CBD and CBG. Hempyre has also agreed to acquire select beverage and topical brands in the United Kingdom and China and has actively been hiring local executive talent.

Hempyre’s management team is led by Mr. Shannon Soqui, Chief Executive Officer, and Mr. Jason Roth, Chief Strategy Officer. Mr. Soqui was formerly the Chief Executive Officer of QIND, and Mr. Roth was the Co-Founder, Chairman, and Chief Executive Officer of Mile High Labs until October 2019.

Mr. Soqui has 25 years of experience advising and financing emerging growth companies in disruptive markets, including retail and consumer packaged goods. Mr. Soqui has worked exclusively in the cannabis and hemp industry since 2014, after a successful 25-year career in Silicon Valley as an investment banker with firms such as Credit Suisse and UBS, a securities lawyer with Brobeck, Phleger & Harrison, and a CPA with KPMG.

“As hemp becomes legal in more countries, we see a tremendous opportunity for a branded consumer packaged goods platform focused on beauty, beverages, and wellness in selected markets,” said Mr. Soqui. “With a focus on high quality products that are legally compliant, tested and safe, and developing a broad global distribution platform, both wholesale and online, we believe that we will be well positioned to develop brand recognition globally.”

Mr. Roth has 25 years of experience owning consumer packaged goods and medical device companies that have operated internationally, and is respected for his strategic leadership and disciplined approach to driving revenue.

“The European beverage market has very attractive business and financial dynamics given the recent legalization of hemp-infused beverages in the United Kingdom and other parts of Europe,” said Mr. Roth. “Asia is also a very attractive market for us. Our partnerships with major distribution partners and key opinion leaders will enable us to reach hundreds of millions of consumers very effectively.”

About Hempyre

Hempyre is an emerging global provider of branded hemp-formulated consumer packaged goods focused on Beauty, Beverage, and Wellness. Hempyre’s Beauty product line focuses on consumer hemp-formulated topical solutions to protect and rejuvenate their skin and body. Hempyre’s Beverage product line focuses on consumers who are looking for healthy ways in which to consume hemp-formulated distilled alcoholic and non-alcoholic spirits, sparkling and live sodas, pressed juices, water, and other ready-to-drink offerings. Hempyre’s Wellness product line focuses on consumers looking for hemp-derived CBD and CBG alternatives to treat anxiety, inflammation, insomnia, pain, or to manage and regulate their overall health.

Hempyre’s core strategy focuses on product branding and distribution in Europe, China, the U.S., and the Asia-Pacific region, while outsourcing most aspects of raw material production and finished goods manufacturing. Hempyre currently has 11 brands with more than 150 product SKUs across its three product segments. Hempyre’s hemp-formulated products are non-psychoactive and are made from high quality strains of hemp oil extracts containing either pure CBD or CBG, or combined with a broad or full spectrum of hemp compounds, including other cannabinoids and terpenes.

Hempyre’s primary operating subsidiaries are located in London, England, and Portland, Oregon, with additional staff in Hong Kong, and Auckland, New Zealand. With its licenses and permits, and given the emerging legalization of hemp-formulated products, Hempyre exports selected hemp-formulated CBD and CBG products from the U.S. to selected developed countries globally. Hempyre’s U.S. operations are licensed as a hemp handler by the Oregon Department of Agriculture, and act as a base for distribution throughout the U.S., with shipment enabled by the USPS. For raw material production and finished goods manufacturing, Hempyre’s strategy is to rely on farmers and concentrate processors in the U.S. for raw materials, and GMP-certified co-packers and white-label manufacturers for finished goods assembly or production. Hempyre’s hemp-formulated CBD and CBG products are distributed through its global network of distributors and wholesalers, its own and third-party owned e-commerce websites, Company-leased storefronts, and a variety of brick and mortar mainstream retailers. For more information visit www.hempyre.com.

Strategic Opportunities:

Hempyre is interested in discussing potential acquisitions of branded product and/or distribution companies in the Beauty, Beverage, or Wellness segments that could infuse CBD and CBG into their products.

Please contact jason@hempyre.com for information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S. Media Contact:
Mr. Erik Ritchie
media@hempyre.com
888-743-6797

U.K. Media Contact:
Mr. William Draper
media@hempyre.com
+44 (0) 800 020 9806

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release

Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release

Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat

Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release

Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu

LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release

LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release

VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye